Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Feb;30(2):161-9.
doi: 10.1111/dme.12100.

Primary and secondary prevention of Type 1 diabetes

J S Skyler  1
Affiliations
Review

Primary and secondary prevention of Type 1 diabetes

J S Skyler. Diabet Med. 2013 Feb.

Abstract

Since type 1 diabetes is an immunologically mediated disease, immune intervention should alter the natural history of the disease. This article reviews prevention studies undertaken either prior to any evidence of autoimmunity (primary prevention) or after the development of islet autoantibodies (secondary prevention). Most immune intervention studies have been conducted in recent-onset type 1 diabetes (tertiary prevention), and these are not reviewed herein. The goal of primary and secondary intervention is to arrest the immune process and thus prevent or delay clinical disease. Primary prevention studies have been conducted in infants with high genetic risk. Interventions tested include several dietary manipulations, including infant formulas free of either cow's milk or of bovine insulin, infant formula supplemented with the omega-3-fatty acid docosahexaenoic acid, delayed introduction of gluten-containing foods, and vitamin D supplementation. Secondary prevention studies have been conducted in both children and adults with diabetes autoantibodies. Interventions tested include nicotinamide, insulin injections, oral insulin, nasal insulin, glutamic acid decarboxylase, and cyclosporine. Underway are secondary prevention studies with teplizumab and with abatacept.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Eisenbarth GS. Banting Lecture 2009. An unfinished journey: molecular pathogenesis to prevention of type 1A diabetes. Diabetes. 2010;59:759–774. - PMC - PubMed
    1. Bluestone JA, Herold K, Eisenbarth G. Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature. 2010;464:1293–1300. - PMC - PubMed
    1. Skyler JS and the Type 1 Diabetes TrialNet Study Group. Update on worldwide efforts to prevent type 1 diabetes. Ann N Y Acad Sci. 2008;1150:190–196. - PMC - PubMed
    1. Leslie RDG, Pyke DA. Immunosuppression of acute insulin-dependent diabetics. In: Irvine WJ, editor. Immunology of Diabetes. Edinburgh: Teviot Scientific Publications Ltd; 1980. pp. 345–347.
    1. Skyler JS. Immune intervention studies in insulin-dependent diabetes mellitus. Diabetes Metab Rev. 1987;3:1017–1035. - PubMed

Publication types

MeSH terms